Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,260,176
  • Shares Outstanding, K 96,630
  • Annual Sales, $ 673,000 K
  • Annual Income, $ -575,000 K
  • EBIT $ -535 M
  • EBITDA $ -504 M
  • 60-Month Beta 0.16
  • Price/Sales 3.36
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 90.08% (+15.75%)
  • Historical Volatility 54.31%
  • IV Percentile 79%
  • IV Rank 35.04%
  • IV High 187.31% on 12/26/25
  • IV Low 37.62% on 09/11/25
  • Expected Move (DTE 18) 2.23 (9.67%)
  • Put/Call Vol Ratio 0.56
  • Today's Volume 217
  • Volume Avg (30-Day) 1,064
  • Put/Call OI Ratio 0.83
  • Today's Open Interest 19,454
  • Open Int (30-Day) 27,962
  • Expected Range 20.79 to 25.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -1.48
  • Number of Estimates 9
  • High Estimate -1.06
  • Low Estimate -2.01
  • Prior Year -1.57
  • Growth Rate Est. (year over year) +5.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.60 +17.42%
on 02/13/26
25.82 -10.84%
on 02/03/26
-1.74 (-7.03%)
since 02/02/26
3-Month
18.41 +25.04%
on 12/29/25
39.89 -42.29%
on 12/08/25
-10.45 (-31.22%)
since 12/02/25
52-Week
18.41 +25.04%
on 12/29/25
43.22 -46.74%
on 03/03/25
-19.90 (-46.37%)
since 02/28/25

Most Recent Stories

More News
Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit Seeks Recovery for Investors; April 6, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP

Did you buy RARE common stock between August 3, 2023, and December 26, 2025?

RARE : 23.02 (-1.58%)
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , March 2, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical...

RARE : 23.02 (-1.58%)
Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE

LOS ANGELES , March 2, 2026 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against  Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ: ...

RARE : 23.02 (-1.58%)
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

NEW YORK and NEW ORLEANS , Feb. 27, 2026 /PRNewswire/ -- Kahn Swick & Foti , LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ...

RARE : 23.02 (-1.58%)
RARE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their Options

RARE : 23.02 (-1.58%)
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit

NEW YORK , Feb. 26, 2026 /PRNewswire/ --

RARE : 23.02 (-1.58%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE

NEW YORK , Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such...

RARE : 23.02 (-1.58%)
LEVI & KORSINSKY, LLP: MANAGEMENT CONFIDENCE REPRESENTATIONS CHALLENGED IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION

Time-Sensitive: Allegations Focus on Repeated Assurances Regarding Setrusumab Efficacy

RARE : 23.02 (-1.58%)
Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit: Investors Face April 6, 2026, Deadline

Did you buy RARE common stock between August 3, 2023, and December 26, 2025?

RARE : 23.02 (-1.58%)
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Ultragenyx Pharmaceutical Inc.(RARE) Shareholders

NEW YORK , Feb. 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE).

RARE : 23.02 (-1.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.

See More

Key Turning Points

3rd Resistance Point 23.98
2nd Resistance Point 23.59
1st Resistance Point 23.30
Last Price 23.02
1st Support Level 22.62
2nd Support Level 22.23
3rd Support Level 21.94

See More

52-Week High 43.22
Fibonacci 61.8% 33.74
Fibonacci 50% 30.82
Fibonacci 38.2% 27.89
Last Price 23.02
52-Week Low 18.41

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar